Boule Diagnostics (Sweden) Performance
| BOUL Stock | SEK 9.06 0.24 2.72% |
Boule Diagnostics has a performance score of 4 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.91, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Boule Diagnostics are expected to decrease slowly. On the other hand, during market turmoil, Boule Diagnostics is expected to outperform it slightly. Boule Diagnostics right now shows a risk of 3.29%. Please confirm Boule Diagnostics treynor ratio, value at risk, and the relationship between the sortino ratio and maximum drawdown , to decide if Boule Diagnostics will be following its price patterns.
Risk-Adjusted Performance
Insignificant
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Boule Diagnostics AB are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Boule Diagnostics may actually be approaching a critical reversion point that can send shares even higher in April 2025. ...more
| Begin Period Cash Flow | 33 M | |
| Total Cashflows From Investing Activities | -56.4 M |
Boule |
Boule Diagnostics Relative Risk vs. Return Landscape
If you would invest 842.00 in Boule Diagnostics AB on December 24, 2024 and sell it today you would earn a total of 64.00 from holding Boule Diagnostics AB or generate 7.6% return on investment over 90 days. Boule Diagnostics AB is generating 0.1741% of daily returns and assumes 3.2924% volatility on return distribution over the 90 days horizon. Simply put, 29% of stocks are less volatile than Boule, and 97% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Boule Diagnostics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Boule Diagnostics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Boule Diagnostics AB, and traders can use it to determine the average amount a Boule Diagnostics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0529
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BOUL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.29 actual daily | 29 71% of assets are more volatile |
Expected Return
| 0.17 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 4 96% of assets perform better |
Based on monthly moving average Boule Diagnostics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Boule Diagnostics by adding it to a well-diversified portfolio.
Boule Diagnostics Fundamentals Growth
Boule Stock prices reflect investors' perceptions of the future prospects and financial health of Boule Diagnostics, and Boule Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Boule Stock performance.
| Return On Equity | 0.0335 | |||
| Return On Asset | 0.0271 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.05 % | |||
| Current Valuation | 562.26 M | |||
| Shares Outstanding | 38.83 M | |||
| Price To Earning | 24.26 X | |||
| Price To Book | 1.06 X | |||
| Price To Sales | 0.68 X | |||
| Revenue | 463.34 M | |||
| EBITDA | 55.69 M | |||
| Cash And Equivalents | 38.18 M | |||
| Cash Per Share | 0.87 X | |||
| Total Debt | 50.6 M | |||
| Debt To Equity | 46.00 % | |||
| Book Value Per Share | 11.91 X | |||
| Cash Flow From Operations | 43.28 M | |||
| Earnings Per Share | 0.96 X | |||
| Total Asset | 572.03 M | |||
| Retained Earnings | (6 M) | |||
| Current Asset | 135 M | |||
| Current Liabilities | 70 M | |||
About Boule Diagnostics Performance
Assessing Boule Diagnostics' fundamental ratios provides investors with valuable insights into Boule Diagnostics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Boule Diagnostics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Boule Diagnostics AB , a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. Boule Diagnostics AB was founded in 1956 and is headquartered in Spnga, Sweden. Boule Diagnostics operates under Image Processing classification in Sweden and is traded on Stockholm Stock Exchange.Things to note about Boule Diagnostics performance evaluation
Checking the ongoing alerts about Boule Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Boule Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Boule Diagnostics had very high historical volatility over the last 90 days | |
| About 13.0% of the company shares are held by company insiders |
- Analyzing Boule Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Boule Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Boule Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Boule Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Boule Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Boule Diagnostics' stock. These opinions can provide insight into Boule Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Boule Stock Analysis
When running Boule Diagnostics' price analysis, check to measure Boule Diagnostics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boule Diagnostics is operating at the current time. Most of Boule Diagnostics' value examination focuses on studying past and present price action to predict the probability of Boule Diagnostics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boule Diagnostics' price. Additionally, you may evaluate how the addition of Boule Diagnostics to your portfolios can decrease your overall portfolio volatility.